HC Wainwright Issues Negative Forecast for Immunome Earnings

Key Points

• HC Wainwright lowered its FY2026 EPS forecast for Immunome to a loss of $2.64 per share from a loss of $2.45, while retaining a Buy rating. Its estimates project losses through FY2030, though narrowing to $0.42 per share.
• Immunome reported a quarterly loss of $0.76 per share, missing the consensus estimate of a $0.62 loss by $0.14.
• Analyst views are mostly positive: 14 rate the stock Buy, one Hold and one Sell, for a consensus “Moderate Buy” rating and a $33.85 price target.

Immunome, Inc. (NASDAQ:IMNM - Free Report) - Equities researchers at HC Wainwright dropped their FY2026 EPS estimates for Immunome in a note issued to investors on Tuesday, November 10th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($2.64) for the year, down from their previous forecast of ($2.45). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Immunome's current full-year earnings is ($2.48) per share. HC Wainwright also issued estimates for Immunome's Q4 2026 earnings at ($0.76) EPS, FY2027 earnings at ($2.71) EPS, FY2028 earnings at ($2.41) EPS, FY2029 earnings at ($1.63) EPS and FY2030 earnings at ($0.42) EPS.

Immunome (NASDAQ:IMNM - Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.14).

IMNM has been the topic of a number of other research reports. Weiss Ratings restated a "sell (d-)" rating on shares of Immunome in a report on Thursday, October 15th. Stifel Nicolaus decreased their price target on Immunome from $24.00 to $23.00 and set a "hold" rating on the stock in a research note on Tuesday. Wedbush reaffirmed an "outperform" rating and set a $35.00 price objective on shares of Immunome in a research report on Tuesday, October 27th. Truist Financial boosted their price target on shares of Immunome from $37.00 to $38.00 and gave the stock a "buy" rating in a research note on Wednesday, August 12th. Finally, Piper Sandler reduced their price objective on Immunome from $33.00 to $30.00 and set an "overweight" rating on the stock in a research note on Tuesday. Fourteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Immunome presently has a consensus rating of "Moderate Buy" and a consensus target price of $33.85.

Immunome Price Performance

Shares of Immunome stock opened at $19.07 on Thursday. The business has a 50 day simple moving average of $20.99 and a two-hundred day simple moving average of $22.30. Immunome has a 12 month low of $16.11 and a 12 month high of $30.06. The stock has a market capitalization of $2.17 billion, a P/E ratio of -7.22 and a beta of 2.68.

Hedge Funds Weigh In On Immunome

A number of large investors have recently bought and sold shares of IMNM. BlackRock Inc. acquired a new position in Immunome during the 2nd quarter worth approximately $186,588,000. Primecap Management Co. CA purchased a new stake in shares of Immunome during the 2nd quarter worth approximately $97,081,000. Bank of America Corp DE purchased a new stake in shares of Immunome during the 2nd quarter worth approximately $13,729,000. Parkman Healthcare Partners LLC acquired a new stake in shares of Immunome in the 2nd quarter worth approximately $12,591,000. Finally, Wellington Management Group LLP grew its holdings in shares of Immunome by 10.1% in the 2nd quarter. Wellington Management Group LLP now owns 5,210,216 shares of the company's stock worth $110,404,000 after acquiring an additional 478,239 shares during the period. Hedge funds and other institutional investors own 44.58% of the company's stock.

Insider Activity at Immunome

In other news, insider Jack Higgins sold 13,200 shares of the stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $25.32, for a total transaction of $334,224.00. Following the completion of the sale, the insider owned 65,050 shares in the company, valued at approximately $1,647,066. This represents a 16.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 7.21% of the company's stock.

More Immunome News

These are some of the IMNM news items that stood out recently:

• Neutral Sentiment: Price targets were trimmed but remain above the $19.07 reference price: Piper Sandler cut its target from $33 to $30 and kept an Overweight rating; Stifel Nicolaus lowered its target from $24 to $23 and maintained Hold. The cuts are cautious, while the ratings and targets indicate potential upside. Piper Sandler target article Stifel Nicolaus article
• Negative Sentiment: HC Wainwright reduced its Q4 2026 EPS forecast to a loss of $0.76 per share from a loss of $0.68, and cut its FY2026 estimate to a loss of $2.64 from $2.45. It also lowered estimates for FY2027–FY2030, including changing its FY2029 forecast from $0.40 profit to a $1.63 loss and its FY2030 forecast from $1.08 profit to a $0.42 loss. These revisions point to a longer path to profitability and could weigh on investor sentiment.

About Immunome

Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company's research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.